Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years

Journal of Hypertension

Volumn 24, Issue 5, 2006, Pages 905-913

  Strand, Arne H ^a   Gudmundsdottir, Helga ^a   Os, Ingrid ^a   Smith, Gunnar ^a   Westheim, Arne S ^a   Bjørnerheim, Reidar ^a   Kjeldsen, Sverre E ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Diastolic dysfunction; Hypertension; Left ventricular hypertrophy; Sympathetic nervous system

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; NEUROHORMONE; NITRATE; NORADRENALIN;

ADRENALIN BLOOD LEVEL; ADRENERGIC SYSTEM; ADULT; ANTIHYPERTENSIVE THERAPY; ARTERIAL BLOOD; ARTICLE; BLOOD PRESSURE; BODY BUILD; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLE; ECHOCARDIOGRAPHY; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MALE; ONSET AGE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE;

EID: 33646370233     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000222761.07477.7b     Document Type: Article

References (42)

1. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105:173-178.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med 1989; 110:101-107.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
4. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998; 32:1454-1459.
5. Weber KT, Brilla CG, Cleland JG, Cohn JN, Hansson L, Heagerty AM, et al. Cardioreparation and the concept of modulating cardiovascular structure and function. Blood Press 1993; 2:6-21.
6. Glasser SP. Hypertension, hypertrophy, hormones, and the heart. Am Heart J 1998; 135:S16-S20.
7. Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma V. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 2003; 166:345-349.
8. Struthers AD. Aldosterone: cardiovascular assault. Am Heart J 2002; 144 (suppl):S2-S7.
9. Rossi GP, Cavallin M, Nussdorfer GG, Pessina AC. The endothelin-aldosterone axis and cardiovascular diseases. J Cardiovasc Pharmacol 2001; 38 (suppl 2):S49-S52.
10. Kelm M, Schafer S, Mingers S, Heydthausen M, Vogt M, Motz W, et al. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens 1996; 14:1357-1364.
11. Greenwood JP, Scott EM, Stoker JB, Mary DA. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol 2001; 38:1711-1717.
12. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108:560-565.
13. Rostrup M, Smith G, Bjornstad H, Westheim A, Stokland O, Eide I. Left ventricular mass and cardiovascular reactivity in young men. Hypertension 1994; 23 (suppl):I168-I171.
14. Briest W, Homagk L, Rassler B, Ziegelhoffer-Mihalovicova B, Meier H, Tannapfel A, et al. Norepinephrine-induced changes in cardiac transforming growth factor-beta isoform expression pattern of female and male rats. Hypertension 2004; 44:410-418.
15. Briest W, Holzl A, Rassler B, Deten A, Leicht M, Baba HA, et al. Cardiac remodeling after long term norepinephrine treatment in rats. Cardiovasc Res 2001; 52:265-273.
16. Patel MB, Stewart JM, Loud AV, Anversa P, Wang J, Fiegel L, et al. Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation 1991; 84:2091-2100.
17. Os I, Kjeldsen SE, Westheim A, Lande K, Norman N, Hjermann I, et al. Endocrine and haemodynamic responses to graded dopamine infusion in essential hypertension. Scand J Clin Lab Invest 1987; 47:371-377.
18. Os I, Kjeldsen SE, Aakesson I, Skjoto J, Eide I, Hjermann I, et al. Evidence of age-related variation in plasma vasopressin of normotensive men. Scand J Clin Lab Invest 1985; 45:263-268.
19. Os I, Kjeldsen SE, Westheim A, Akesson I, Eide I, Skjoto J, et al. Aging and urinary vasopressin excretion in healthy men. Scand J Urol Nephrol 1987; 21:235-239.
20. Os I, Kjeldsen SE, Westheim A, Aakesson I, Norman N, Enger E, et al. Decreased central dopaminergic activity in essential hypertension. J Hypertens 1987; 5:191-197.
21. Peuler JD, Johnson GA. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci 1977; 21:625-636.
22. Kjeldsen SE, Flaaten B, Eide I, Helgeland A, Leren P. Evidence of increased peripheral catecholamine release in patients with long-standing, untreated essential hypertension. Scand J Clin Lab Invest 1982; 42:217-223.
23. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
24. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58:1072-1083.
25. Wachtell K, Smith G, Gerdts E, Dahlof B, Nieminen MS, Papademetriou V, et al. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint. Am J Cardiol 2000; 85:466-472.
26. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Association of carotid atherosclerosis and left ventricular hypertrophy. J Am Coll Cardiol 1995; 25:83-90.
27. Nishimura RA, Abel MD, Hatle LK, Tajik AJ. Assessment of diastolic function of the heart: background and current applications of Doppler echocardiography. Part II. Clinical studies. Mayo Clin Proc 1989; 64:181-204.
28. Appleton CP, Jensen JL, Hatle LK, Oh JK. Doppler evaluation of left and right ventricular diastolic function: a technical guide for obtaining optimal flow velocity recordings. J Am Soc Echocardiogr 1997; 10:271-292.
29. Munagala VK, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR, Redfield MM. Association of newer diastolic function parameters with age in healthy subjects: a population-based study. J Am Soc Echocardiogr 2003; 16:1049-1056.
30. Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 2004; 43:169-175.
31. Kjeldsen SE, Schork NJ, Leren P, Eide IK. Arterial plasma norepinephrine correlates to blood pressure in middle-aged men with sustained essential hypertension. Am Heart J 1989; 118:775-781.
32. Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 1983; 5:86-99.
33. Marcus R, Krause L, Weder AB, Dominguez-Meja A, Schork NJ, Julius S. Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. Circulation 1994; 90:928-936.
34. Olsen MH, Wachtell K, Hermann KL, Frandsen E, Dige-Petersen H, Rokkedal J, et al. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Am Heart J 2002; 144:530-537.
35. Kjeldsen SE, Mundal R, Sandvik L, Erikssen G, Thaulow E, Erikssen J. Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men. J Hypertens 2001; 19:1343-1348.
36. Grassi G, Seravalle G, Dell'Oro R, Turri C, Bolla GB, Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000; 36:538-542.
37. Reims HM, Kjeldsen SE, Brady WE, Dahlof B, Devereux RB, Julius S, et al. Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study. J Hum Hypertens 2004; 18:381-389.
38. Reims HM, Oparil S, Kjeldsen SE, Devereux RB, Julius S, Brady WE, et al. Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. Blood Press 2004; 13:376-384.
39. Messerli FH, Sundgaard-Riise K, Ventura HO, Dunn FG, Oigman W, Frohlich ED. Clinical and hemodynamic determinants of left ventricular dimensions. Arch Intern Med 1984; 144:477-481.
40. Oh JK, Appleton CP, Hatle LK, Nishimura RA, Seward JB, Tajik AJ. The noninvasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 1997; 10:246-270.
41. Rostrup M, Westheim A, Kjeldsen SE, Eide I. Cardiovascular reactivity, coronary risk factors, and sympathetic activity in young men. Hypertension 1993; 22:891-899.
42. Sandvik L, Erikssen J, Thaulow E, Erikssen G, Mundal R, Rodahl K. Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. N Engl J Med 1993; 328:533-537.